Css LLC Il Has $1.83 Million Stake in Johnson & Johnson (NYSE:JNJ)

Css LLC Il raised its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 20.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 12,627 shares of the company's stock after purchasing an additional 2,180 shares during the quarter. Css LLC Il's holdings in Johnson & Johnson were worth $1,826,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in JNJ. First Heartland Consultants Inc. bought a new position in Johnson & Johnson in the 4th quarter valued at approximately $1,269,000. Ames National Corp bought a new position in shares of Johnson & Johnson during the fourth quarter valued at $1,903,000. White Knight Strategic Wealth Advisors LLC lifted its holdings in shares of Johnson & Johnson by 93.0% during the fourth quarter. White Knight Strategic Wealth Advisors LLC now owns 53,264 shares of the company's stock worth $7,703,000 after purchasing an additional 25,663 shares during the period. Mpwm Advisory Solutions LLC bought a new stake in shares of Johnson & Johnson in the fourth quarter worth $484,000. Finally, Principal Street Partners LLC increased its holdings in Johnson & Johnson by 3.1% in the fourth quarter. Principal Street Partners LLC now owns 34,532 shares of the company's stock valued at $4,994,000 after purchasing an additional 1,044 shares during the period. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Trading Up 0.7%

Shares of Johnson & Johnson stock opened at $153.58 on Wednesday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $169.99. The stock has a 50 day moving average price of $155.87 and a two-hundred day moving average price of $153.80. The stock has a market capitalization of $369.52 billion, a PE ratio of 23.09, a price-to-earnings-growth ratio of 2.56 and a beta of 0.42.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, beating analysts' consensus estimates of $2.59 by $0.18. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The business had revenue of $21.89 billion during the quarter, compared to analyst estimates of $21.65 billion. As a group, equities analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th will be issued a dividend of $1.30 per share. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.24. This represents a $5.20 dividend on an annualized basis and a yield of 3.39%. The ex-dividend date is Tuesday, May 27th. Johnson & Johnson's payout ratio is currently 57.84%.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on JNJ shares. The Goldman Sachs Group raised Johnson & Johnson from a "neutral" rating to a "buy" rating and increased their price target for the company from $157.00 to $172.00 in a research note on Wednesday, April 9th. Royal Bank of Canada reissued an "outperform" rating and set a $181.00 target price on shares of Johnson & Johnson in a research report on Wednesday, April 16th. Leerink Partners lowered shares of Johnson & Johnson from an "outperform" rating to a "market perform" rating and lowered their price target for the stock from $169.00 to $153.00 in a report on Tuesday, May 13th. Argus raised shares of Johnson & Johnson to a "strong-buy" rating in a research note on Friday, January 24th. Finally, Sanford C. Bernstein reissued a "market perform" rating on shares of Johnson & Johnson in a research note on Wednesday, April 16th. Eleven equities research analysts have rated the stock with a hold rating, seven have given a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $170.88.

Insider Transactions at Johnson & Johnson

In related news, VP Robert J. Decker sold 6,999 shares of the company's stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the completion of the sale, the vice president now owns 21,001 shares in the company, valued at approximately $3,483,645.88. This represents a 25.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 0.16% of the company's stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.